Gahl WA, Bashan N, Tietze F, Schulman JD (1984) Lysosomal cystine counter-transport in heterozygotes for cystinosis
For those with moderate to severe deficiency, this is especially critical
Light penetration depth in biological tissues is limited
In the context of existing neuroinflammatory disease, infection, organ injury/failure, and/or systemic inflammation, can perpetuate further cerebral vascular and CNS injury
In September 2023 the FDA placed it in Category 2 of its 503A interim bulk-substances policy, effectively excluding it from the compounding bulk-substances list, so it is not eligible for pharmacy compounding for human use
the mixture is concentrated in vacuo until distillation stops, the contents are cooled to below 40C, dichloromethane (16 kg) is added and the reactor contents at about 20 (15-25) are agitated for at least 1 hour